LifeMD (NASDAQ:LFMD) Releases Earnings Results

LifeMD (NASDAQ:LFMD) posted its earnings results on Monday. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.02, Zacks reports. LifeMD updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

LifeMD Stock Down 8.6 %

LFMD stock opened at $4.27 on Tuesday. The firm has a market cap of $184.94 million, a price-to-earnings ratio of -6.67 and a beta of 1.50. LifeMD has a 12-month low of $3.99 and a 12-month high of $12.88. The company’s fifty day simple moving average is $5.64 and its 200 day simple moving average is $5.37.

Analysts Set New Price Targets

LFMD has been the topic of several analyst reports. Mizuho initiated coverage on shares of LifeMD in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $7.00 price objective on the stock. KeyCorp reduced their price objective on shares of LifeMD from $10.00 to $7.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Lake Street Capital initiated coverage on shares of LifeMD in a research note on Tuesday, December 10th. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of LifeMD in a research note on Monday, November 11th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, LifeMD has an average rating of “Moderate Buy” and an average price target of $11.14.

Insider Activity at LifeMD

In related news, CEO Justin Schreiber sold 50,000 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $7.55, for a total value of $377,500.00. Following the transaction, the chief executive officer now owns 2,653,715 shares in the company, valued at $20,035,548.25. The trade was a 1.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 15.97% of the stock is owned by company insiders.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.